Screener
Prime Medicine PRME Q3 2026 earnings
Reported November 12, 2026 · After market close
Revenue$4.2MBeat by $2.9M
EPS-$0.22Beat by $0.02
Revenue estimate$1.3M
EPS estimate-$0.24
“Having demonstrated through our CGD program that Prime Editing can correct disease-causing mutations in humans ex vivo, we are now extending that experience in vivo, beginning with our liver directed programs. Furthermore, the FDA clearance of our IND for PM647 in Alpha-1 Antitrypsin Deficiency further underscores the versatility of our universal liver LNP platform. In just months, our two wholly owned liver programs have moved into, or been cleared for, clinical development, underscoring both the productivity of our platform and our ability to translate scientific innovation into clinical programs.”
Next report
Date not yet announcedValuation & ratios
Segments
By segment
Versus estimates
Revenue
Diluted EPS
FAQ
- When did Prime Medicine report Q3 2026 earnings?
- Prime Medicine (PRME) reported Q3 2026 earnings on November 12, 2026 after market close.
- What were Prime Medicine's Q3 2026 revenue and EPS?
- Prime Medicine reported revenue of $4.2M and eps of $-0.22 for Q3 2026.
- Did Prime Medicine beat estimates in Q3 2026?
- Revenue beat the consensus estimate of $1.3M by $2.9M. EPS beat the consensus estimate of $-0.24 by $0.02.
- How did Prime Medicine's Q3 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 243.9% from $1.2M a year earlier and eps grew 31.3% from $-0.32.
- Where can I find Prime Medicine's Q3 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-072713) and the 10-Q periodic report (0001628280-26-073392) directly on SEC EDGAR. The filing index links above go to sec.gov.
